“RXRX combines next-gen AI drug discovery, multiple near-term catalysts, and a strategic entry point that smart money won’t ignore”
Let’s talk about Recursion Pharmaceuticals (RXRX) – a story that’s getting more interesting by the day. Look, the biotech space is getting hammered, and RXRX has taken its share of hits. Their recent earnings miss ($0.34 vs expected $0.33) didn’t help matters. But here’s what’s catching my eye – and why you need to pay … Continued